GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant
Ilon Liu,Gustavo Alencastro Veiga Cruzeiro,Lynn Bjerke,Rebecca F Rogers,Yura Grabovska,Alexander Beck,Alan Mackay,Tara Barron,Olivia A Hack,Michael A Quezada,Valeria Molinari,McKenzie L Shaw,Marta Perez-Somarriba,Sara Temelso,Florence Raynaud,Ruth Ruddle,Eshini Panditharatna,Bernhard Englinger,Hafsa M Mire,Li Jiang,Andrezza Nascimento,Jenna LaBelle,Rebecca Haase,Jacob Rozowsky,Sina Neyazi,Alicia-Christina Baumgartner,Sophia Castellani,Samantha E Hoffman,Amy Cameron,Murry Morrow,Quang-De Nguyen,Giulia Pericoli,Sibylle Madlener,Lisa Mayr,Christian Dorfer,Rene Geyeregger,Christopher Rota,Gerda Ricken,Keith L Ligon,Sanda Alexandrescu,Rodrigo T Cartaxo,Benison Lau,Santhosh Uphadhyaya,Carl Koschmann,Emelie Braun,Miri Danan-Gotthold,Lijuan Hu,Kimberly Siletti,Erik Sundström,Rebecca Hodge,Ed Lein,Sameer Agnihotri,David D Eisenstat,Simon Stapleton,Andrew King,Cristina Bleil,Angela Mastronuzzi,Kristina A Cole,Angela J Waanders,Angel Montero Carcaboso,Ulrich Schüller,Darren Hargrave,Maria Vinci,Fernando Carceller,Christine Haberler,Irene Slavc,Sten Linnarsson,Johannes Gojo,Michelle Monje,Chris Jones,Mariella G Filbin
DOI: https://doi.org/10.1016/j.ccell.2024.08.006
IF: 50.3
2024-08-27
Cancer Cell
Abstract:Diffuse hemispheric gliomas, H3G34R/V-mutant (DHG-H3G34), are lethal brain tumors lacking targeted therapies. They originate from interneuronal precursors; however, leveraging this origin for therapeutic insights remains unexplored. Here, we delineate a cellular hierarchy along the interneuron lineage development continuum, revealing that DHG-H3G34 mirror spatial patterns of progenitor streams surrounding interneuron nests, as seen during human brain development. Integrating these findings with genome-wide CRISPR-Cas9 screens identifies genes upregulated in interneuron lineage progenitors as major dependencies. Among these, CDK6 emerges as a targetable vulnerability: DHG-H3G34 tumor cells show enhanced sensitivity to CDK4/6 inhibitors and a CDK6-specific degrader, promoting a shift toward more mature interneuron-like states, reducing tumor growth, and prolonging xenograft survival. Notably, a patient with progressive DHG-H3G34 treated with a CDK4/6 inhibitor achieved 17 months of stable disease. This study underscores interneuronal progenitor-like states, organized in characteristic niches, as a distinct vulnerability in DHG-H3G34, highlighting CDK6 as a promising clinically actionable target.